<DOC>
	<DOCNO>NCT01052831</DOCNO>
	<brief_summary>This study evaluate effectiveness naltrexone reduce ICD symptom Parkinson 's disease patient take dopamine agonist .</brief_summary>
	<brief_title>Naltrexone Impulse Control Disorders Parkinson 's Disease</brief_title>
	<detailed_description>Impulse control disorder ( ICDs ) , include compulsive gambling , sexual behavior , buying , eat , increasingly recognize significant clinical problem Parkinson 's disease ( PD ) , occur 15 % patient . Dopamine agonist ( DA ) treatment think primary risk factor development ICDs PD . ICDs often lead significant impairment psychosocial functioning , interpersonal relationship , quality life . The management ICDs context PD complex . Patients may reluctant discontinue DA treatment due motor benefit derive treatment , patient often chronic symptom . Thus , additional treatment approach need . A medication show efficacious treatment ICDs minimal impact parkinsonism would allow many ICD patient continue full-dose DA treatment . Naltrexone , long-acting opioid receptor antagonist , help treatment alcohol opioid dependence . In addition , placebo-controlled study demonstrate helps treatment pathological gamble general population . Opioids regulate dopamine pathway area brain link impulse control disorder , opioid antagonist block opioid receptor region . In study , 48 PD patient ICD treat either naltrexone ( 50-100 mg/day ) placebo period 8 week . The study ass naltrexone improves ICD symptom PD well tolerate . To knowledge , propose study first control trial agent treat ICDs PD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Disruptive , Impulse Control , Conduct Disorders</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Inclusion Criteria 1 . Diagnosis possible probable idiopathic Parkinson 's disease ( PD ) . 2 . Ages 1885 year . 3 . Diagnosis compulsive gambling , buying , sex behavior , eat &gt; 2 month duration . 4 . Impulse control disorder ( ICD ) behavior begin PD onset context dopamine agonist ( DA ) treatment . 5 . Current stable DA use . Participants must DA 6 month stable dose ( change ) 1 month prior enrol study . 6 . Subjects capable give informed consent , support significant cognitive impairment base Montreal Cognitive Assessment score â‰¥24 . 7 . Willingness maintain exist PD pharmacotherapy regimen duration study . Exclusion Criteria 1 . Active suicide ideation . 2 . Anticipated need initiate antidepressant therapy course study ( must dose therapeutic range least 2 month . If patient end need start antidepressant change antidepressant dose course study , he/she allow continue study participation ) . 3 . ICD behavior severe modification DA treatment clinically warrant , judge PI . 4 . Deep brain stimulation surgery past year . 5 . Evidence significant liver disease chart review patient history ( e.g. , cirrhosis , chronic hepatitis , liver transplant , liver cancer ) . 6 . Meeting diagnostic criterion alcohol opiate dependence . 7 . Meeting diagnostic criterion Dopamine Dysregulation Syndrome . 8 . Use opioids pain management . 9 . Females pregnant , plan become pregnant , breastfeed include study . Females child bear potential need verify pregnant negative urine pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Compulsive Gambling</keyword>
	<keyword>Compulsive Buying</keyword>
	<keyword>Compulsive Shopping</keyword>
	<keyword>Compulsive Eating</keyword>
	<keyword>Hypersexuality</keyword>
	<keyword>Dopamine Agonists</keyword>
	<keyword>Mirapex</keyword>
	<keyword>Pramipexole</keyword>
	<keyword>Requip</keyword>
	<keyword>Ropinirole</keyword>
	<keyword>Impulse Control Disorders</keyword>
</DOC>